Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

PHASE3CompletedINTERVENTIONAL
Enrollment

149

Participants

Timeline

Start Date

April 18, 2013

Primary Completion Date

September 2, 2013

Conditions
Primary HypercholesterolemiaMixed Dyslipidemia
Interventions
BIOLOGICAL

Evolocumab Pre-filled Syringe

Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.

BIOLOGICAL

Evolocumab AI/pen

Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.

Trial Locations (26)

13104

Research Site, Manlius

13210

Research Site, Syracuse

16635

Research Site, Duncansville

19446

Research Site, Lansdale

30328

Research Site, Atlanta

30342

Research Site, Atlanta

33173

Research Site, Miami

33952

Research Site, Port Charlotte

38305

Research Site, Jackson

43302

Research Site, Marion

43907

Research Site, Cadiz

46320

Research Site, Hammond

57701

Research Site, Rapid City

75231

Research Site, Dallas

77074

Research Site, Houston

91360

Research Site, Thousand Oaks

91361

Research Site, Westlake Village

91436

Research Site, Encino

93003

Research Site, Ventura

97123

Research Site, Hillsboro

04210

Research Site, Auburn

N5W 6A2

Research Site, London

M8V 3X8

Research Site, Toronto

M9V 4B4

Research Site, Toronto

N4S 5P5

Research Site, Woodstock

H9R 3J1

Research Site, Pointe-Claire

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY